Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Rodríguez, César  [Clear All Filters]
2023
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodríguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023.
Nooka AK, Kaufman JL, Rodríguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, et al. A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2023.
2022
Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodríguez C, et al. Stem cell mobilization yields with daratumumab and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2022.
2020
Bar M, Ott SM, E Lewiecki M, Sarafoglou K, Wu JY, Thompson MJ, Vaux JJ, Dean DR, Saag KG, Hashmi SK, et al. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
Voorhees PM, Kaufman JL, Laubach JPeter, Sborov DWeston, Reeves B, Rodríguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, et al. Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. Blood. 2020.
Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, Ciurea SOctavian, Holtzman NG, Ii GLPhillips, Devine SM, et al. Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
2019
Díaz-Guerra E, Moreno-Jiménez EP, de Rojas I, Rodríguez C, Rodríguez-Traver E, Arribas-González E, Orera M, Hernández I, Ruiz A, Vicario C. A collection of four integration-free iPSC lines derived from diagnosed sporadic Alzheimer's disease patients with different APOE alleles. Stem Cell Res. 2019;39:101522.
Rodríguez-Traver E, Díaz-Guerra E, Rodríguez C, Fernández P, Arenas F, Araúzo-Bravo M, Orera M, Kulisevsky J, Moratalla R, Vicario C. A collection of integration-free iPSCs derived from Parkinson's disease patients carrying mutations in the GBA1 gene. Stem Cell Res. 2019;38:101482.
Rodríguez-Traver E, Díaz-Guerra E, Rodríguez C, Arenas F, Orera M, Kulisevsky J, Moratalla R, Vicario C. A collection of three integration-free iPSCs derived from old male and female healthy subjects. Stem Cell Res. 2019;42:101663.
Rodríguez-Traver E, Rodríguez C, Díaz-Guerra E, Arenas F, Araúzo-Bravo M, Orera M, Kulisevsky J, Moratalla R, Vicario C. Generation of an integration-free iPSC line, ICCSICi005-A, derived from a Parkinson's disease patient carrying the L444P mutation in the GBA1 gene. Stem Cell Res. 2019;40:101578.
Díaz-Guerra E, Oria-Muriel MA, Moreno-Jiménez EP, de Rojasb I, Rodríguez C, Rodríguez-Traver E, Orera M, Hernándezb I, Ruizb A, Vicario C. Generation of an integration-free iPSC line, ICCSICi006-A, derived from a male Alzheimer's disease patient carrying the PSEN1-G206D mutation. Stem Cell Res. 2019;40:101574.
Díaz-Guerra E, Rodríguez-Traver E, Moreno-Jiménez EP, de Rojas I, Rodríguez C, Orera M, Hernández I, Ruiz A, Vicario C. An integration-free iPSC line, ICCSICi007-A, derived from a female Alzheimer's disease patient with the APOE-ε4/ε4 alleles. Stem Cell Res. 2019;41:101588.